Analyst Chris Schott from J.P. Morgan maintained a Hold rating on Biogen and keeping the price target at $175.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Chris Schott’s rating is based on a combination of factors that reflect both the current challenges and future potential of Biogen. The company is facing difficulties with its core portfolio, and the growth of its key products, Leqembi and Skyclarys, has been slower than anticipated. Despite these hurdles, there is a long-term opportunity for Leqembi, especially in the prevention market, but significant uptake is not expected until beyond 2025.
Additionally, while there are potential catalysts on the horizon, such as the approval and increased use of blood-based biomarkers and subcutaneous induction for Leqembi, these are not expected to have a major impact until 2026. The stock has also underperformed compared to the broader group, and with few catalysts in 2025 to change investor sentiment, Schott remains cautious. Consequently, he has issued a Hold rating, reflecting a neutral stance on the stock’s near-term prospects.
Schott covers the Healthcare sector, focusing on stocks such as Pfizer, Regeneron, and Teva Pharmaceutical. According to TipRanks, Schott has an average return of 1.5% and a 50.63% success rate on recommended stocks.
In another report released yesterday, Morgan Stanley also maintained a Hold rating on the stock with a $146.00 price target.